Statin Management with Paxlovid
For lovastatin and simvastatin: stop at least 12 hours before starting Paxlovid, hold during the 5-day treatment course, and restart 5 days after completing Paxlovid. For atorvastatin: consider stopping during the 5-day Paxlovid course only—no pre-treatment or post-treatment holding period needed. For rosuvastatin: continue without interruption.
Statin-Specific Recommendations
Lovastatin and Simvastatin (Contraindicated)
- Stop 12 hours before initiating Paxlovid 1, 2
- Hold throughout the 5-day Paxlovid treatment
- Resume 5 days after completing Paxlovid 1, 2
- Rationale: Co-administration is contraindicated due to risk of myopathy including rhabdomyolysis from massive drug level increases 1, 2
Atorvastatin (Requires Management)
- No pre-treatment holding required 1, 2
- Consider temporary discontinuation during the 5-day Paxlovid course 1, 2
- Resume immediately after completing Paxlovid—no post-treatment waiting period 1, 2
- Alternative approach: If continuing atorvastatin, reduce dose substantially:
- Rationale: Ritonavir increases atorvastatin exposure 4.76-fold by inhibiting CYP3A4 metabolism 3
Rosuvastatin (Minimal Interaction)
- No dose adjustment or holding period needed 3
- Continue regular dosing throughout Paxlovid treatment
- Rationale: Only mild pharmacokinetic changes (1.94-fold Cmax increase, unchanged AUC) with no clinically significant impact 3
Pravastatin, Fluvastatin, Pitavastatin
- Generally safe to continue as these statins are not significantly metabolized by CYP3A4
- No specific holding recommendations in FDA labeling
Clinical Context
The ritonavir component of Paxlovid is a potent CYP3A4 inhibitor that rapidly blocks statin metabolism, particularly for lovastatin, simvastatin, and atorvastatin 1, 2, 4. Even a short 5-day course creates significant drug interaction risk 4.
Common pitfall: Forgetting the 5-day post-treatment holding period for lovastatin/simvastatin. Ritonavir's inhibitory effects persist beyond the treatment course, requiring this additional safety margin 1, 2.
Practical consideration: In real-world primary care settings, statins were the most frequently implicated drug class requiring management (25.6% of interactions), with discontinuation being the most common intervention (53% of cases) 5.
Risk-Benefit Balance
The cardiovascular risk from brief statin interruption (5-15 days total) is negligible compared to the myopathy/rhabdomyolysis risk from drug interaction 4. For high-risk COVID-19 patients who need Paxlovid, temporary statin modification should not delay antiviral initiation 4.